Jade Biosciences, Inc. (JBIO)

Jade Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Net Income	-93.96
Stock-Based Compensation	2.51
Other Operating Activities	25.2
Change in Accounts Payable	2.58
Change in Other Net Operating Assets	18.44
Operating Cash Flow	-45.23
Total Debt Issued	190
Net Debt Issued (Repaid)	190
Other Financing Activities	-6
Financing Cash Flow	184
Net Cash Flow	138.77
Change in Working Capital	21.02

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q